Key result
OKT3 retreatment for refractory cardiac allograft rejection achieved total resolution on initial follow-up biopsy in 75% of patients, with an 83% one-year survival rate.
Why the study?
Does OKT3 retreatment improve refractory cardiac allograft rejection in patients previously exposed to OKT3?
Population
12 cardiac allograft recipients with refractory rejection who had previously been exposed to OKT3, out of…
Design
Case_series
Follow-up
1 year
Authors
Loading...
OKT3 retreatment may support refractory rejection management in prior-exposed patients; hypothesis-generating and should not yet change practice.
Observational (n=12)
Does OKT3 retreatment improve refractory cardiac allograft rejection in patients previously exposed to OKT3?
OKT3 retreatment is effective for refractory cardiac allograft rejection in patients previously exposed to the drug, successfully eliminating CD3+ lymphocytes and improving histology.
O’Connell et al. (1989) conducted an observational in Refractory cardiac allograft rejection (n=12). OKT3 retreatment was evaluated on Total resolution of rejection on initial follow-up biopsy. OKT3 retreatment for refractory cardiac allograft rejection achieved total resolution on initial follow-up biopsy in 75% of patients, with an 83% one-year survival rate.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: